Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
Adverse events will be closely watched when full data are reported.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
A key pivotal study of bemarituzumab will read out shortly.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
On a wing and a prayer Leap heads for phase 3.